Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 41

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 2
Chunk 41
---
 succeed in achieving its stated
goals under all potential future conditions.

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

29

PART
II – OTHER INFORMATION

ITEM
1. LEGAL PROCEEDINGS

From
time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we
do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition, or results
of operations.

ITEM
1A. RISK FACTORS

In
addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed
in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025,
which is available at www.sec.gov. Any of the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended December
31, 2024 could materially affect our business, financial condition or future results, and such risk factors may not be the only risks
we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially
adversely affect our business, financial condition or future results. We do not undertake to update any of the “forward-looking”
statements or to announce the results of any revisions to these “forward-looking” statements except as required by law.

ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On
April 23, 2025, the Company issued 25,000 shares of its common stock to a marketing firm and 78,816 shares of its common stock to an
investor relations firm for services rendered under consulting agreements. The shares were issued
with an aggregate grant date fair value of $66,000. The shares issued to these consultants are restricted and bear a Rule 144
legend.

On
June 10, 2025, the Company approved the grant of 250,000 options pursuant to the Company